By specifically targeting the affected cells or tissues, the drug can be delivered directly to the site of action, increasing its effectiveness while minimizing side effects on healthy cells.

Drug antigenicity refers to the ability of a drug to stimulate an immune response in an individual due to its chemical structure.

There are several different types of pharmaceutical patents that can be granted.

Protein sulfation is a post-translational modification, where a sulfate group gets added to a specific amino acid residue in a protein.

Fast track designation (FTD) is a process used by the U.S. Food and Drug Administration (FDA) tofacilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

The U.S. FDA offers Fast Track Designation and Breakthrough Therapy Designation to speed up the development and review of drugs for serious conditions lacking treatments. Yet, they differ in key aspects.

Protein palmitoylation is a post-translational modification that involves the addition of a 16-carbon saturated fatty acid, typically palmitate (C16:0), to cysteine residues within target proteins.

Ubiquitination is a process that involves adding a protein called ubiquitin to a substrate protein.

Prodrugs are pharmacologically inactive compounds that are converted into an active drug after administration within the body.

The terms New Molecular Entity (NME) and New Chemical Entity (NCE) are sometimes used interchangeably; however, they are distinct.

In the U.S. FDA context, "Requirement/Commitment Status" generally refers to a manufacturer's or sponsor's obligations for regulatory approval, post-approval studies, or marketing authorization conditions for drugs, devices, or regulated products.

The combination of multiple drugs can have significant effects on drug delivery.